2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2327

Delivering ESCAPE-Pain (Enabling Self-Management and Coping of Arthritic Pain through Exercise ) – an Online Guide for Healthcare Professionals
Abstract Number: 1422

Demographic Differences in Health Related Information Technology Use Among Patients with Rheumatic Diseases
Abstract Number: 2292

Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Abstract Number: 1503

Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501
Abstract Number: 2264

Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial
Abstract Number: 1795

Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-over Group in the Extension of the Denosumab Pivotal Fracture Trial
Abstract Number: 195

Dependence on Walking Aids and Patient-Reported Outcomes after Total Knee Arthroplasty
Abstract Number: 196

Dependence on Walking Aids Is Associated with Pain and Mobility Limitation after Total Hip Arthroplasty
Abstract Number: 1742

Depletion of Reactive Oxygen Species Biases T Cells to Proinflammatory Cytokine Production in Rheumatoid Arthritis
Abstract Number: 653

Dermal Injury Promotes Nephritis Flare in Lupus-Prone NZM2328 Mice
Abstract Number: 113

Dermatologic Rheumatism: Our Experience with a Multidisciplinary Dermatology/Rheumatology Clinic
Abstract Number: 1995

Design and Implementation of a Clinical Teaching Tool for Approach to Children with Suspected New Rheumatologic Diagnosis
Abstract Number: 143

Detailed Anatomical Distribution of Synovial Inflammation Revealed By Ultrasound in Patients with Blau Syndrome
Abstract Number: 2339

Detecting Inflammation in Vivo Using Activatable Fluorescence Contrast Agents in Inflammatory Arthritis
Abstract Number: 4

Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].